Ematologia5 articoli

Impatto 2

Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant

Pubblicato: 2026-12-01

Journal of medical economics

MediLens Indicizzato: 2026-05-23

This retrospective study assessed the costs and healthcare resource utilization associated with switching from frontline pegaspargase/cal-aspargase pegol to second-line recombinant asparaginase in pediatric and AYA patients with acute lymphoblastic leukemia (ALL). A total of 154 patients were ide...

Leggi su PubMed

Impatto 2

Hungry bone syndrome-like state following denosumab in a patient with multiple myeloma.

Pubblicato: 2026-07-01

JCEM case reports

MediLens Indicizzato: 2026-05-23

This case study presents a 76-year-old man with newly diagnosed multiple myeloma who experienced severe, prolonged hypocalcemia following denosumab treatment. The patient had elevated creatinine and calcium levels prior to treatment, and developed significant mineral imbalances despite aggressive...

Leggi su PubMed

Impatto 3

Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.

Pubblicato: 2026-05-22

Hematology/oncology and stem cell therapy

MediLens Indicizzato: 2026-05-23

Hypophosphatemia is prevalent in patients undergoing CAR-T therapy, occurring in 71.5% of recipients. The condition is linked to an increased risk of immune effector cell-associated neurotoxicity syndrome (ICANS), with a hazard ratio of 2.87. Notably, hypophosphatemia typically precedes ICANS by ...

Leggi su PubMed

Impatto 2

Haploidentical donor versus double-unit cord blood transplantation in hematologic malignancies: comparative survival and graft-versus-host disease outcomes from a decade of real-world experience.

Pubblicato: 2026-05-22

BMC cancer

MediLens Indicizzato: 2026-05-23

This study compares haploidentical donor (HID) and double-unit umbilical cord blood (DUCB) transplantation in 97 patients with hematologic malignancies. HID recipients had faster neutrophil and platelet recovery and lower rates of grade II-IV acute GVHD compared to DUCB recipients. However, overa...

Leggi su PubMed

Impatto 2

The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.

Pubblicato: 2026-05-22

Hematology/oncology and stem cell therapy

MediLens Indicizzato: 2026-05-23

This study evaluates the outcomes of 32 myelofibrosis patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) using a two-step transplant approach. The approach resulted in favorable 1-year and 5-year overall survival rates of 83% and 68%, respectively, and reduced nonrel...

Leggi su PubMed

Tendenze della Ricerca Medica

Ematologia5 articoli

Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant

Hungry bone syndrome-like state following denosumab in a patient with multiple myeloma.

Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.

Haploidentical donor versus double-unit cord blood transplantation in hematologic malignancies: comparative survival and graft-versus-host disease outcomes from a decade of real-world experience.

The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis.

Ricevi riassunti giornalieri personalizzati